Galectin Therapeutics unveils new data on galectin-3 inhibitor belapectin for MASH cirrhosis and cancer therapy

Reuters12-06

Galectin <a href="https://laohu8.com/S/LENZ">Therapeutics</a> unveils new data on galectin-3 inhibitor belapectin for MASH cirrhosis and cancer therapy

Galectin Therapeutics Inc. has released a corporate presentation highlighting its focused pipeline in the development of galectin-based therapeutics for chronic liver diseases and cancer. The company's lead candidate, belapectin, is a galectin-3 inhibitor with Fast Track Designation and patent protection through 2032. Clinical data indicate significant efficacy in patients with MASH cirrhosis, especially those without varices, showing a notable reduction in the development of new varices compared to placebo. Belapectin is also being evaluated in combination with Keytruda for melanoma and head and neck cancer, with encouraging clinical responses reported. The presentation also describes ongoing preclinical efforts to develop oral galectin-3 inhibitors. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief on December 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589810817?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-06 05:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589810817","market":"us","top_or_hot":-1,"title":"Galectin Therapeutics unveils new data on galectin-3 inhibitor belapectin for MASH cirrhosis and cancer therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Galectin <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> unveils new data on galectin-3 inhibitor belapectin for MASH cirrhosis and cancer therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GALT\">Galectin Therapeutics Inc</a>. has released a corporate presentation highlighting its focused pipeline in the development of galectin-based therapeutics for chronic liver diseases and cancer. The company's lead candidate, belapectin, is a galectin-3 inhibitor with <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation and patent protection through 2032. Clinical data indicate significant efficacy in patients with MASH cirrhosis, especially those without varices, showing a notable reduction in the development of new varices compared to placebo. Belapectin is also being evaluated in combination with Keytruda for melanoma and head and neck cancer, with encouraging clinical responses reported. The presentation also describes ongoing preclinical efforts to develop oral galectin-3 inhibitors. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief on December 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Galectin Therapeutics unveils new data on galectin-3 inhibitor belapectin for MASH cirrhosis and cancer therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGalectin Therapeutics unveils new data on galectin-3 inhibitor belapectin for MASH cirrhosis and cancer therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-06 05:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Galectin <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> unveils new data on galectin-3 inhibitor belapectin for MASH cirrhosis and cancer therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/GALT\">Galectin Therapeutics Inc</a>. has released a corporate presentation highlighting its focused pipeline in the development of galectin-based therapeutics for chronic liver diseases and cancer. The company's lead candidate, belapectin, is a galectin-3 inhibitor with <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> Designation and patent protection through 2032. Clinical data indicate significant efficacy in patients with MASH cirrhosis, especially those without varices, showing a notable reduction in the development of new varices compared to placebo. Belapectin is also being evaluated in combination with Keytruda for melanoma and head and neck cancer, with encouraging clinical responses reported. The presentation also describes ongoing preclinical efforts to develop oral galectin-3 inhibitors. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief on December 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL2yFFXm:1","article_id":"2589810817","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589810817","pubTimestamp":1764969309,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Galectin Therapeutics Inc. has released a corporate presentation highlighting its focused pipeline in the development of galectin-based therapeutics for chronic liver diseases and cancer. The company's lead candidate, belapectin, is a galectin-3 inhibitor with Fast Track Designation and patent protection through 2032. Clinical data indicate significant efficacy in patients with MASH cirrhosis, especially those without varices, showing a notable reduction in the development of new varices compared to placebo. Belapectin is also being evaluated in combination with Keytruda for melanoma and head and neck cancer, with encouraging clinical responses reported. The presentation also describes ongoing preclinical efforts to develop oral galectin-3 inhibitors. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-g","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GALT":"Galectin Therapeutics Inc"},"translate_title":"Galectin Therapeutics公布了galectin-3抑制剂belapectin用于MASH肝硬化和癌症治疗的新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GALT":0.9},"content_text":"Galectin Therapeutics unveils new data on galectin-3 inhibitor belapectin for MASH cirrhosis and cancer therapy\n    \n\nGalectin Therapeutics Inc. has released a corporate presentation highlighting its focused pipeline in the development of galectin-based therapeutics for chronic liver diseases and cancer. The company's lead candidate, belapectin, is a galectin-3 inhibitor with Fast Track Designation and patent protection through 2032. Clinical data indicate significant efficacy in patients with MASH cirrhosis, especially those without varices, showing a notable reduction in the development of new varices compared to placebo. Belapectin is also being evaluated in combination with Keytruda for melanoma and head and neck cancer, with encouraging clinical responses reported. The presentation also describes ongoing preclinical efforts to develop oral galectin-3 inhibitors. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief on December 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589810817","isCrawlerRequest":true}